With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

The region's best workplaces put integrity, inclusion, and respect at the center of their workplace culture.

Great-Places-To-Work-Asia-2025_Team Photo_Becton Dickinson(BD)

<p>Becton Dickinson ranks No. 11 on the 2025 Best Companies to Work For Southeast Asia.</p>

Fortune 100 Best Companies To Work For – Southeast Asia

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

America's Most Innovative Companies

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

World's Most Admired Companies

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 200 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-177-Becton Dickinson

The multinational medical company orchestrates multiple divisions that supply institutions, laboratories, and companies with goods and services for medical research.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-187-Becton-Dickinson

Medical tech company Becton Dickinson makes devices and instruments that are used by health care professionals and medical researchers. Among its products are reagents used in testing for COVID-19.

As we face unprecedented collective challenges, cooperation has become a business superpower.

36.CTW20.BD

As a major manufacturer of medical supplies, from injection devices to the medication delivery systems used in ICUs, BD has been in overdrive lately—in some cases making more of a product in a single week that it had during the whole previous year, to meet COVID-19 demand. But BD has gone beyond merely ramping up. It has installed medical equipment at emergency field hospitals; it has provided infection surveillance data to the CDC; and it has worked with governments and NGOs worldwide to get immunization supplies ready for the eventual arrival of a vaccine.

Change the World

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune 500 marks the 62nd running of the list.

Here’s our look at 50 companies that do well by doing good.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Change The World

Impact Segment

Sector

Prior Year Rank

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Culture rank

Process rank

Product rank

Years on list

Previous rank

Best Companies To Work For Southeast Asia

Type of organization

CEO/Top executive

Group headquarters

HQ location

GPTW national list

Woman CEO

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Becton Dickinson develops, manufactures, and sells a wide range of medical devices, lab equipment, diagnostic products, surgical products, sharps disposal systems, and other medical supplies, serving health care institutions, researchers, and the general public worldwide.

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Becton Dickinson (BDX): Company Profile, Stock Price, News, Rankings

legacy

Becton Dickinson

becton dickinson

Good day, everyone. Welcome to today's conference call to discuss BD's First Quarter Fiscal twenty twenty five Earnings and BD's announcement of its intent to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 30486 for domestic calls and area code (402) 220-7223 for international calls. For today's call, all parties have been placed in a listen only mode until the question and answer session. I will now turn the call over to Mr.

Greg Rodidis, Senior Vice President, Treasurer and Head of Investor Relations. Please go ahead, sir.

Good morning, and welcome to BD's earnings call. I'm Gregory Yidis, Senior Vice President, Treasurer and Head of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at bd.com. We have a lot of exciting news to discuss today.

Yesterday afternoon, we issued two press releases. The first discusses our first quarter results of fiscal twenty twenty five. The second announces our intention to separate BD's biosciences and diagnostic solutions business. The press releases and accompanying presentations can be accessed on the IR website at investors.bd.com. For the purposes of today's call, we have posted a combined presentation and will be providing slide reference cues to assist you in following along with our prepared remarks.

In connection with the separation announcement, the company has decided to postpone its Investor Day, previously scheduled for 02/26/2025, to allow BDU to focus on the transaction. The company expects to provide a comprehensive update on strategy and outlook in the future closer to this operation. Leading today's call are Tom Poland, BDU's Chairman, Chief Executive Officer and President and Chris Dolorafis, Executive Vice President and Chief Financial Officer. Following this morning's prepared remarks, Tom and Chris will be joined for Q and A by our segment presidents Mike Garrison, President of the Medical segment Mike Feld, President of the Life Sciences segment and Rick Berg, President of the Interventional segment. Before we get started, I want to remind you that we will be making forward looking statements.

You can read the disclaimer in our earnings release and the disclosures in our SEC filings available on the Investor Relations website. Unless otherwise specified, all comparisons will be made on a year over year basis versus the relevant fiscal period. Revenue percentage changes are on an FX neutral basis unless otherwise noted. Reconciliations between GAAP and non GAAP measures are included in the appendices of the earnings release and presentations. With that, let's turn to Slide five.

And I am very pleased to turn it over to Tom.

Thanks, Greg, and good morning, everyone. We have a number of significant updates to share on how we are creating value through our BD2025 strategy. This includes yesterday's announcement of the planned separation of our biosciences and diagnostic solutions business, our strong Q1 results, updated fiscal twenty twenty five guidance and progress on our innovation pipeline. So let's jump right in. Starting with our Q1 results, we continue to demonstrate strong execution, exceeding each of our financial goals.

This includes 9.6% revenue growth or 3.9% organic. We delivered three seventy basis points and three forty basis points of adjusted gross and operating margin expansion respectively and 28% growth in adjusted diluted EPS to $3.43 Chris will provide more color on our Q1 results, but I'd like to take a moment to thank our team whose execution and momentum of BDXcellence is powering continued strong margin expansion, earnings and cash flow performance. We returned over $1,000,000,000 to shareholders in Q1. This includes $300,000,000 in dividends and a $750,000,000 accelerated share buyback, which we see as a value creating action based on our view of BD's intrinsic value. With strong operational performance in Q1 and confidence in the year, we affirmed our full year currency neutral and organic revenue growth guidance.

Our Q1 outperformance enables us to de risk growth expectations for the second half and also raise the midpoint of our reported EPS guidance despite incremental translational currency impacts. Moving to Slide six. Innovation is core to our growth strategy and we continue to make strong progress against our pipeline. I'd like to share an update on some key milestones. In BD Medical, we continue to progress our Connected Care strategy and as planned submitted the next five ten for our BD Alaris infusion system that enables over the air software updates and includes a new ETCO2 module.

BDOLARIS is the only infusion system with an integrated ETCO2 module, enhancing patient safety by monitoring their respiratory system and pausing the pump when necessary to reduce the risk of opioid overdose. The pace and impact of innovation also continues to be strong in advanced patient monitoring, where we received five ten clearance on the next gen Hemasphere Ulta monitor and the new SwanIQ and ForesightIQ smart sensors. In BDI, we continue to advance our strategy in advanced tissue regeneration and expand into new applications. Most recently, we received EU approval for the prevention of incisional hernias using the PHASICS resorbable mesh. This makes PHASICS the first resorbable mesh with a broad indication for preventing incisional hernias.

Our U. S. Trial remains underway. We also enrolled the first patients in our GALAFLEX capsular contraction prevention clinical trial. This product is BD's first in a series of new innovations using our reservable biomaterial to improve outcomes in patients undergoing breast surgery.

Finally, in life sciences, we continue to advance our strong cycle of innovation and remain on track to launch the first BDFAX discover analyzer, the A8 in the second half of this fiscal year. Additionally, in our molecular diagnostics portfolio, we're continuing to advance our position in the $2,000,000,000 high volume molecular testing market. Our BDON CLARITY HPV assay is the only test with extended genotyping to be FDA approved for self collection. And we're seeing accelerating sales funnel momentum as a result of recent changes in U. S.

Cervical Cancer Screening guidelines and increased U. S. Reimbursement. Before I turn it over to Chris to provide further color on our financials and outlook, I want to again express my appreciation of our team's strong work in advancing our BD2025 strategy, a strong quarter and for what's ahead.

Thanks, Tom. Echoing Tom's comments, I'm truly excited about our plan to separate biosciences and diagnostic solutions. It's an exciting next step in our strategy that we believe can unlock significant value for both new BD and biosciences and diagnostic solutions. Both businesses will be positioned to thrive in their respective markets and deliver value for all stakeholders, shareholders, employees, and of course, our customers and the patients they serve.

Let me start on Slide seven and our Q1 results. Strong execution drove revenue, margin and earnings ahead of our expectations. Q1 revenue grew 9.6% or 3.9% organic. Organic growth was led by our MedTech business with about 5% growth driven by volumes and share gains across core devices and strong performance in our growth platforms, including double digit growth in Purwik, peripheral vascular disease and PHASICS. Diagnostic solutions grew modestly as strength in lab automation and momentum in BD Max molecular platform IVD assays was partially offset by respiratory season timing.

Q1 performance also reflects the expected decline in biosciences given market dynamics that reduced research funding in China and The U. S. Regionally, total company organic growth was led by strong performance in The U. S. And was partially offset by the decrease in China predominantly in biosciences.

To allow time to share our perspective on the separation of biosciences and diagnostic solutions and have sufficient time for Q and A, please refer to the slides accompanying today's call for additional performance details by segment. Turning to our P and L results, Q1 adjusted diluted EPS of $3.43 grew 28% driven by strong operational performance ahead of our expectations and the timing of a discrete tax item that was contemplated in our full year tax rate. Consistent with our commitments, we delivered strong margin to start the year with adjusted gross margin of 54.8% and adjusted operating margin of 23.6%, up three seventy basis points and three forty basis points year over year respectively, both ahead of our expectations and fueled by momentum in BD excellence. Strong margin performance continued to enable outsized investments in selling and R and D to drive growth. Regarding cash and capital allocation, free cash flow of approximately 600,000,000 was in line with our expectations and was impacted by the timing of planned one time cash payments.

Full year cash flow continues to be in line with our prior expectations. In the quarter, we returned over $1,000,000,000 to shareholders, including dividends and a seven fifty million dollars accelerated share repurchase. Cash and short term investments at December 31 totaled $728,000,000 We ended the quarter with net leverage of 2.9 times and are on track to meet our deleveraging commitments. Turning to Slide eight and our updated fiscal twenty twenty five guidance. As we look ahead to the balance of the year, we remain focused on driving areas of momentum and continue to monitor transitory market dynamics, notably in China and Biosciences Research funding levels.

We are maintaining our currency neutral total and organic revenue growth guidance. Regarding foreign currency, based on current spot rates for illustrative purposes, we expect a headwind to revenue from translational currency of approximately $250,000,000 for the full fiscal year, which is an increase of approximately $200,000,000 from our prior guidance view. As a result, we now expect fiscal twenty twenty five total revenues to be in a range of $21,700,000,000 to $21,900,000,000 For tax, we now expect our adjusted effective tax rate to be between 1415.25%. On the strength of our Q1 performance, particularly our margin execution and our confidence in the full year, we are increasing the midpoint of our fiscal twenty twenty five adjusted reported EPS guidance. We now expect adjusted reported EPS of $14.3 to $14.6 which reflects growth of 10% at the midpoint.

Our updated EPS guidance reflects an operational increase of $0.175 that is absorbing $0.15 of estimated incremental translational currency. As you think about phasing over the balance of fiscal twenty twenty five, the following are some considerations. Q1 revenue performance allows us to further de risk our second half growth by about 25 basis points. Our expectation for the first half organic revenue growth remains largely unchanged versus our prior expectations with some timing of revenues shifted into Q1. As a reminder, Q2 includes the comparison to prior year licensing revenue, which creates a headwind of nearly 150 basis points.

Excluding licensing, our Q2 organic revenue growth expectation reflects sequential acceleration that is around the midpoint of our full year organic guidance range. We expect strong gross and operating margins in Q2 with solid sequential improvement in adjusted operating margin or about flat year over year inclusive of absorbing the planned licensing comparison. Our updated expectation for Q2 adjusted EPS reflects timing impacts from our updated translational FX assumptions and a tax rate of about 16.8%, which assumes a ratable rest of year tax rate. In summary, our strategy is demonstrating strong momentum and we are delivering on our commitments. I will now turn it back to Tom starting on Slide 10 to provide further detail on the exciting news announcing our intention to separate our biosciences and diagnostic solutions business.

Thank you, Chris. Building off our strong performance in the quarter, I'd like to share more details about our plan to separate BD's Biosciences and Diagnostic Solutions business to enhance strategic focus, drive growth through targeted capital deployment and unlock significant value for what will become the new BD and the separated business. This separation decision was the result of a comprehensive business portfolio evaluation launched in early twenty twenty four. And this is the next natural step of our evolution, building on the strong foundation and momentum of BD2025 and the high growth platforms we've built and have been scaling. The new BD will be well positioned as a pure play med tech company with leading positions in large attractive end markets.

With this added focus, we're excited about the opportunity for new BD to drive concentrated capital deployment in high impact R and D as well as growth accretive M and A, which positions us to deliver differentiated and durable growth rates in medtech. At the same time, we're also excited about the opportunity for biosciences and diagnostic solutions to realize its full market potential as a pure play leader in life science tools and diagnostics, continuing to accelerate growth through its strong innovation pipeline and industry leading solutions. As we turn to slide 11, let me start by setting some context on why this is the next natural step in our evolution, building on the strong foundation and momentum of BD2025. Over the past five years, we've been transforming into a faster growing, more profitable organization positioned at the forefront of long term growth trends. We've been systematically increasing our WAMGR and long term growth by intentionally shifting our portfolio mix towards higher growth markets and executing against a strong innovation pipeline.

In fact, by the end of this year, we're on track to have more than doubled new product revenue since the launch of BD 2025. We established and honed our M and A and divestiture capabilities, deploying about $7,000,000,000 in capital to complete 20 value creating transactions since 2020. These include the spin off of IMBECTA, the sale of our surgical instruments business, Vmueller, and the acquisitions of the Edwards Life Sciences Critical Care Product Group, Parata Systems, Straub Medical, TIFA and others. We created an embedded BDXcellence, simplifying our operations and enabling us to deliver on aggressive long term margin expansion targets. Through our disciplined capital deployment strategy, we've built significant balance sheet capacity and strengthened cash flows allowing us to both invest in our business and return capital to shareholders through competitive dividends, value creating tuck in M and A and share repurchases.

This was all achieved while advancing our quality systems and putting customer centricity at the heart of how we plan and operate throughout BD. We've achieved 70% reduction in non conformances and a 25% reduction in field actions since launching BD2025. Moving on to Slide 12. We have also built and have been scaling multiple new growth platforms as part of BD2025. These platforms are directly linked to the most critical areas of healthcare, such as connected care, new care settings and addressing chronic diseases, and are some of the platforms which will reshape our growth profile for the long term.

Over 25% of BD revenue now comes from platforms that are growing high single digits or more, and this is just the beginning as we continue to expand our exposure to higher growth categories. Moving to Slide 13, we are well on track to exceed every financial target established at our twenty twenty one Analyst Day, and we have outperformed historical averages. In November 2021, we targeted a base organic revenue CAGR of 5.5% plus through 2025. Based on the midpoint of this year's guidance, we expect to deliver 5.9%. We targeted an increase of base operating margins by 400 basis points through 2025.

And in fiscal year twenty twenty two, we increased the target to five forty basis points. We are on track to deliver five sixty basis points of margin expansion to margins of 25% plus. We also targeted double digit base adjusted EPS CAGR and now expect to be well over double digits at 13.8%. On to Slide 14. This track record creates momentum as we move into our next phase of value creation and positions both new BD and the Biosciences and Diagnostic Solutions business to focus and win in attractive growth categories.

Let me start by sharing a perspective on the profile of the new BD. The new company will be a med tech leader with scale and global reach across the $70,000,000,000 plus addressable market growing at about 5%. Each day, new BD will touch more patients than any other med tech company in the world, including over ninety percent of patients admitted to a U. S. Hospital.

We expect new BD will have an accelerating growth profile, attractive margins and a best in class recurring revenue profile of over 90%. The separation will also enable enhanced focus with targeted investment and a tailored capital deployment strategy towards attractive high growth categories. This will be complemented by our strong execution, driving continued margin expansion and cash generation through BD excellence. As I look over at the Biosciences and Diagnostic Solutions business, it's expected to be a leader across an attractive $22,000,000,000 plus addressable market, growing at mid to high single digits. We expect the business to have a highly attractive growth and margin profile with more than 80% recurring revenue.

We will also have an opportunity to further accelerate its strong innovation pipeline in markets with significant growth potential and realize its full market potential as a pure play life science tools and diagnostics business. Turning to slide 15, let's go deeper on the new BD, a $17,800,000,000 med tech leader. On to slide 16, We plan to organize new BD into four operating segments, each being market leaders in attractive end markets with significant headroom for growth. First, Medical Essentials will consist of our medication delivery solutions and specimen management businesses that truly represent the backbone of healthcare delivery. These are our products such as IV catheters, picks, flush, syringes, IV sets and blood collection systems.

We are the market leader in each of these spaces, manufacturing tens of billions of devices each year, resulting in durable recurring revenue and strong cash generation. Second, Connected Care will include our Medication Management Solutions business, which includes our pharmacy automation platform and our advanced patient monitoring business with millions of smart devices that use automation, artificial intelligence and analytics to improve the efficiency and effectiveness of patient care and creates compelling growth potential in new areas. Third, Biopharma Systems will bring a new name and increase focus to our Pharmaceutical Systems business unit, which is the global leader in biologic drug delivery, developing and manufacturing drug delivery devices for the pharmaceutical industry. Biopharma Systems is uniquely positioned to enable the transition to more biologics, including GLP-one treatments and capitalize on the large growth potential of pharmaceutical industry trends as more drugs launches rely on patient self injection. Fourth is the interventional segment, which will include our urology and critical care, peripheral intervention and surgery businesses that advance the treatment of high burden chronic conditions such as urinary incontinence, peripheral vascular disease, cancer and tissue reconstruction, all of which are high growth categories with attractive margin profiles and meaningful headroom for new innovation.

We'll share more about timing of this new segment structure as we near completion of the transaction. On to Slide 17, we have an exciting and robust innovation pipeline across the new BD segments with a significant number of $50,000,000 plus revenue opportunities, fueling above market performance. The new BD will have a meaningful runway for additional new innovation and growth, both organically and through growth accretive tuck in M and A. In conclusion, as we turn to slide 18, new BD will deliver a durable and differentiated mid single digit growth profile, supported by attractive end markets and best in class recurring revenue. We will continue to systematically increase WAMGR through disciplined capital allocation and our BDXcellence operating system will continue to enable investments in growth and meaningful margin expansion with the majority being realized from gross margin.

And our targeted financial profile will support strong earnings growth and value creation. Let's move to Biosciences and Diagnostic Solutions on Slide 19. We are excited by the opportunity this separation has to unlock meaningful value for customers, the business and shareholders. Turning to slide 20. The opportunity here is an attractive $22,000,000,000 plus addressable segment.

The businesses have strong portfolios and pipelines and are positioned well for growth. Biosciences and Diagnostic Solutions operate in a market growing mid to high single digits with more than 80% recurring revenue and expected 30% adjusted EBITDA margins. Now turning to Slide 21. Each of these businesses are leaders in large attractive markets. Biosciences had $1,500,000,000 in FY 'twenty four revenue, addressing a $7,000,000,000 plus market with 6% to 7% category growth.

Diagnostic Solutions had $1,800,000,000 in FY 'twenty four, addressing a $15,000,000,000 plus market with about 6% to 7% category growth. As we turn to Slide 22, biosciences is the undisputed pioneer that created the modern field of flow cytometry, helping scientists revolutionize our understanding of cell biology in the fields of cancer, infectious disease and immune health, and enabling countless breakthrough therapies. Scientists and clinicians around the world continue to rely on our flow cytometry platforms and reagents to enable the next generation of discoveries, including through our new facts discover flow cytometry platform. Biosciences has a very strong innovation pipeline of future facts discover instruments, new antibodies, dyes and assays. This includes continuing to scale our single cell multiomics platforms with a significant increase in commercial headcount to support strong double digit growth.

Moving to Diagnostic Solutions, this business is a pioneer in microbiology research and clinical diagnostics with multiple world firsts in advancing the diagnosis of conditions such as sepsis, TB, COVID and other infections, and in applying robotics and AI to advance infectious disease testing. This primarily comprised of our microbiology and molecular diagnostics platforms, which both have strong innovation pipelines. Our molecular portfolio is among the leaders in the high growth molecular market and is anchored by the BD core high throughput and BD max medium throughput systems. Our BD Core plus our OnClarity HPV assays offer a complete paradigm shift in cervical cancer screening, and it starts with the ease of self collection. Overall, this business is well positioned to create value under multiple types of separation structures where the investments and deployment of capital are entirely focused on the life science industry.

Turning to slide 23. Now, I want to talk more about the milestones of the separation. Moving into slide 24. In terms of the form the separation could take, we are committed to exploring all opportunities to execute the separation in a manner that maximizes shareholder value. Separation options include a reverse Morris Trust, sale, spin off or other transaction.

We expect to announce more specifics on the separation plans by the end of fiscal twenty twenty five and are targeting to complete the transaction in fiscal twenty twenty six. As the company pursues this separation, we remain focused on execution and continuing to operate the Biosciences and Diagnostic Solutions businesses and the other BD businesses consistent with our BD 2025 strategy, including continued investments in commercial growth, innovation, M and A and other initiatives that are part of the company's multi year strategic operating plan. Finally, turning to Slide '25. We are excited about what the future holds for new BD and the Biosciences and Diagnostic Solutions businesses as we established two strategically aligned entities with mission critical portfolios to maximize impact. In summary, we believe the separation has the potential to unlock value through simplification, enhanced focus and tailored investment in capital allocation.

We believe New BD will have an enhanced strategic focus and growth oriented portfolio that positions the company for long term value creation. And as a pure play life science tools and diagnostics business, we believe biosciences and diagnostic solutions will realize its full market potential, while continuing to accelerate growth. In the meantime, we continue to execute against our fiscal year twenty twenty five plan as seen in our Q1 performance. Thank you for joining and for your continued interest and support. I look forward to our next chapter and to sharing more specific details upon formalizing the form of the transaction.

With that, we'll open it up to questions.

Thank We'll go first this morning to Travis Steed of Bank of America.

Hey, congrats on the spend. Hey, good morning. Congrats on the spend. I guess one question for Tom on the spend. Why now?

How you're thinking about the different separation options, spend versus sell and how you manage the dis synergies? And then Chris, wanted to ask on the Q2 guide. Looks like 2.75% on revenue, but you've got the 150 basis point licensing headwind. And is there still the 50 to 75 basis points in China Farm Systems? Just trying to get the kind of the true underlying growth on Q2?

Thanks, Travis. I'll start and then turn it to Chris. So, obviously, we're really excited about both the performance in Q1 as well as the announcement today on the new BD and the separation and the opportunities ahead for our life science business. Just as we step back, this process started in the first half of FY 'twenty four as we really took time to reflect on the strong progress that we've had been making against our BD 2025 strategy as we were coming into our last year.

As I discussed on the call, BD 2025 has really transformed BD into more faster

organization, positioned at the profitable organization, positioned at the forefront of multiple long term growth trends. And those are obviously indicated by a number of the new growth platforms that we've built, whether or not that's our advanced patient monitoring business, our urinary incontinence business, peripheral vascular, our tissue reconstruction business that we've built, biology drug delivery, which we are now the world leader in, and pharmacy automation. At the same time, of course, over the last several years, we created and have embedded BD excellence across the company. And you're seeing over the last number of quarters how that's impacting accelerated gross margin performance and cash generation. And this quarter was certainly no exception to that with very strong performance in that camp.

And so as we reflected on that, we've looked at how we've meaningfully increased the intrinsic value of the company through execution of that strategy and looked at ways that we could further extremely excited about this as a next step in unlocking significant value for all of our stakeholders. We believe that the separation both positions New BD as a scaled pure play med tech leader with leading positions in large attractive markets. We see this as the added focus creates an exciting opportunity for new BD to drive concentrated investments not only in high impact R and D, but continued disciplined capital allocation that's allowing us to continue accretive growth in value creating transactions, perhaps even in an accelerated way, as we move forward, all while continuing exceptional progress on our margins and cash generation that will fuel that as well. At the same time, right, BDB and DS are operating from a position of strength, right? This is a decision based on portfolio and really a tremendous opportunity we see to unlock value from these great businesses to create pure play life science tools and diagnostics leaders across the large $22,000,000,000 market growing high mid to high single digits with a very attractive revenue and margin profiles.

So in terms of the form that the transaction will take place, obviously, that's still to be determined and we'll share more information as that advances, which we described should be by the end of FY twenty twenty five. Key is we're open to the transaction formats that best maximize shareholder value creation. That's our number one decision criteria and we'll keep that at the top of our mind as we go through that process.

Yes. And Travis, on the question on sales in Q2, maybe just bigger picture on top line performance. One, it was great to see outperformance in Q1, so really strong start to the year where we're exiting ahead of our plan. If everyone recalls kind of at the start of the year, there were some questions about the ramp. So a couple of things, it's nicely derisked the remaining portion of the year in each quarter, the second half by about 25 basis points.

So think you have a much more balanced top line profile first half to second half. As you think about Q2, you called it out, I mean think of it as a very discrete one time kind of headwind with the prior year licensing comp. If you take that out, we're right at the midpoint of our guidance at 4.25%. And if you think of that more broadly, you do have those market dynamics that are still playing out in the first half of the year, most notably in China, BDD, little bit in Farm Systems. Those Those are directionally worth about that 125 basis points for the year.

It's probably similar in that range in the quarter. So it puts kind of the core business and operating at sort of a five plus level. So right in line, if not ahead of plan and a more de risked revenue profile that we feel good about. Thanks, Travis.

Thank you. We go next now to Larry Biegelsen, Wells Fargo.

Good morning. Thanks for taking the question and congrats on the separation announcement. Tom, I'd love to get your thoughts on the tariffs and the export controls that were announced. So the 10% China tariff, I think, went into effect. And then if the 25% tariff on Mexico and Canada go into effect, what would be the impact on BD and your ability to offset that?

Thanks for the question, Larry. So our largest footprint by far is in North America from a manufacturing perspective and particularly in The U. S. Is by far our largest footprint. Mexico would be playing an important role after that followed by Europe and then Asia.

Obviously, as we think about tariffs, it was positive to see the leaders in The U. S, Mexico and Canada advance their discussions and achieve a temporary resolution this past week. And we continue to monitor this closely inclusive of if any future potential tariffs could include carve outs for medical devices, right, to prevent or could be risks of shortages, wanting to prevent negative impacts to healthcare costs and make sure that public health is protected. I think it's at this point there is no really confirmation in the form or timing of when any tariffs would take place. And so that's something we'll monitor very closely and we can then frame any potential impact of that at that time, but too early at this point and something that we're managing very closely.

Thank you. We next now to Patrick Wood of Morgan Stanley.

Beautiful. Thank you so much taking the question. And congrats obviously on the separation. I guess, and apologies for the crackly voice. I guess, if you end up going down the sale route and with a cash injection, are there any areas that you particularly feel you'd like to bulk up on or parts of the business which you could throw a little bit of extra investment?

And I guess connected to that too is obviously the value of your time internally as a team. Are there any areas of the business where you're going to have a little bit more time on your plates once the process is done? Any areas you kind of get to spend a little bit more time on that you wish you could previously give it a bit more attention? I'd love to hear. Thanks.

Great question, Patrick. I think in terms of priority, let me start with the last component first. If you look at each of our businesses, we've been performing extremely well versus the markets and peers in each of the sectors in which we participate. And so, as we look at the fundamental question of how we've been operating each of the businesses, whether or not it's our core medical businesses, our interventional businesses, our life science businesses, each of them are performing at or above their market growth rates and peer groups. So we feel really strong about how we're performing.

Some of those markets, of course, are in different cycles, like the research spending at this point or last year, but we've been navigating that extremely well, as you look at the broader market growth overall and peer sector. So, as we think about where from a capital allocation perspective, obviously, high growth accretive opportunities are a priority for us. It's been a priority for us as you can see how we've been deploying capital over the last several years. We think our Interventional segment, of course, overall has a number of tremendous market opportunities in it that we have a right to play in and win on that we would look to continue to invest behind. I think certainly there are others, but that whole sector overall is quite attractive and we certainly spend a lot of time focusing and building our funnels in that category.

We'll continue to focus as you know we have been on accelerating our R and D funnel organically as well and that's something we'll continue to allocate our time towards which is making sure that we maximize the value of our new product launches. We've got some really exciting things that we've launched over the last many years and many more things to come as we've discussed whether or not those are in APM, more in the incontinence space, maximizing our penetration and biologics and the wearables category with new launches we have coming there to further new launches in surgery and peripheral vascular. And so making sure that we maximize growth in the sectors that we're in today and then continuing to shift our portfolio into those high growth, high margin accretive spaces. Good news is we find ourselves in NewCo in being in large, very attractive markets where we have very much a right to win in and look forward to that.

Thank you. We go next now to Matt Taylor of Jefferies.

a question. Hey, Matt. Good morning. So the question I wanted to ask was really on the operational performance. Nice start to the year and with the FX headwinds, you weren't able to raise guidance as much as maybe the performance deserve.

I know you called out the ongoing headwinds from China and some of the funding that we've seen. And I was just hoping that you could give us some color on that. I know you didn't change the number, but maybe just talk about the trends in China and some of the headwinds that you've been seeing?

Yes. Thanks for the question. Let me maybe just start bigger picture to your point on Q1 and just the guide and how we were thinking about that. I touched on top line already. Obviously, it's early in the year, really strong start into Q1.

We're ahead of plan. We over delivered on all of our financial metrics. The first point we addressed was this question that was out there at the start of the year on the ramp and we're nicely de risking the second half of growth by 25 basis points and actually even Q2 a little bit. So it provides for a nicer glide path as you think of moving top line throughout the year. The market dynamics to date have been playing out as planned as part of that.

We will come back to your question. Those are areas that of course we continue to monitor. I think the other just two points is when you look down the P and L, I mean this was an exceptionally high quality P and L in operating income, gross margin of 54.8% up three seventy eight basis points, actually above where we exited last year. So you're seeing the benefit of BD excellence play out as expected, even slightly better than planned. So really strong performance there.

That all translated into operating income, EPS. It gave us the confidence to increase operational EPS by nearly $0.18 at the midpoint. And then to your point, look, there's translational FX that everyone's been talking about. We actually have this nicely dialed in. This is pure translation.

It's over a full point on our earnings. And despite that, we're delivering strong double digit EPS growth at 10% at the midpoint. So I think a good start to the year. We increased our guide at the midpoint and we remain focused on executing against that.

And maybe for China, let me turn it to Mike Feld to make some comments there.

Thank you, Tom. As many of you I'm sure have read, our high end facts discover platform was recently impacted by a ban as it directly targets spectral analyzers and analyzers with 26 plus colors. That said, it is important to remember that while the facts discovery portfolio is our newest offering, we do have the most robust lineup of flow cytometers in the world with many models that are not impacted by this ban. The ban also does not impact our clinical and research reagent portfolio or our clinical instrumentation offering anchored by our FAX Lyric platform. Additionally, while we appreciate the U.

S. Government's national security concerns, we believe the previous administration errored in its risk assessment in this case, and we are actively engaging with policymakers during the sixty day commentary period to advocate for a different approach tied to this ban. While not material at the BDX level, this ban was unplanned. We will continue to give updates related to this matter once we know more post the conclusion of the commentary period.

Maybe any commentary on just overall research spending, how we're seeing?

Yes. Overall research spending, it's a cautious scenario for us. We continue to monitor very closely NIA spending, specifically how that impacts grants and the funding of research in The U. S. Market.

Additionally, it's great to remember that we do have a very robust clinical portfolio, as well as many research projects go on for years where we will continue to serve those customers with our research reagents.

Thank you. We go next now to David Roman of Goldman Sachs.

Thank you. Good morning, everybody. I wanted just to dive in a little bit more on some of the end market performance here and what you're just observing as things evolve. I think for some of the sort of problem children businesses that you saw last year, whether that was Farm systems, biosciences, China, you contemplated no improvement in the '25 guidance. But as we kind of start the year, it looks like both biosciences and pharmaceutical systems deteriorated from where you exited 2024.

So maybe you just give us an update on what's happening in these categories and the extent to which you think you can get back to consistent performance, at least what you saw in 2024 and which would imply an improvement to the balance of this year?

Yes. Thanks for the question, David. Let me start with BDB and then Farm Systems. So biosciences, just as you recall, we had not seen the slowdown in research spending at the start of FY 2024. So and we had commented on that as being a dynamic that we would expect, creates more challenging comps in the first half of this year.

And that was a major contributor to our phasing, as we had easier comps in the back half. And that was based upon the strength of the pipeline that we had in BDB. You saw us be impacted by slowdown in research spending on a lag versus peers, probably a six to up to nine to twelve month lag versus what other peers were seeing because of the strength of that funnel that we had built. So that's the number one factor there. I think in terms of so that's a fundamental question of what is the timing of research spend recovery.

And we still want to be cautious on that and we have a cautious outlook built into our budget for the year. That's something we'll continue to monitor very closely both in The U. S. And in China, which are the two major markets that we've seen that research spending slowdown impact those markets. So that's something again that we're poised to capitalize on with a very strong position when those markets do recover.

And that's our focus at this time. In pharma systems, we expect that to begin to recover in the back half of this year. As you've seen a number of companies announce, right, there is still some destocking happening particularly in vaccine categories as there has been some slower vaccine uptake in a number of areas this past year. Those are factors that you are seeing across the market overall. We continue to be extremely well positioned in the biologic space in GLP-1s.

I think our number of GLP-one biosimilar contracts is now up to 50 plus. We continue to make really strong progress there as well as on signing new molecules overall. As we think about the number of biologic drugs that have been clear here in the last several years, we're winning about 80% of those are ending up in BD devices. And that's a fact that we had shared at the beginning of or in the middle of last year. And as we think about molecules approved even to date since then, we continue to maintain that very high win rate there.

So, but that's what we're focused on as those markets recover. We feel very confident in our position to capitalize on those. And again, that's the timing of those is as I described. Thanks, David.

Thank you. We go next now to Robbie Marcus of JPMorgan.

Great. Good morning and congrats on this announcement. I'm sure there's been a lot of work put behind it. Either Chris or Tom, you talk about in the slides the desire this will allow for better streamlined and focused capital allocation. Maybe you could give us some examples of how you're thinking about what that might entail versus the limitations as a combined company today?

Becton Dickinson (BDX) Q1 2025 Earnings Call Transcript

Company Participants